Arrowhead Pharmaceuticals, Inc. ARWR
Set alert
As of Nov 2, 12:52 PM ET
- YTD
- -9.98%
- 1 year
- +40.98%
- Open
- 60.55
- Prev close
- 59.90
- Mkt cap
- 8.44B
- Vol
- 491.20K
- Avg vol
- 1.72M
- EPS
- -2.28
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 59.50
- High
- 61.17
- Forward P/E
- -12.03
- Beta
- 1.30
- Short ratio
- 4.41
- Inst. own
- 85.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 24, 2026
- 50-d avg
- 70.34
- 200-d avg
- 71.76
- 1y target
- 107.71
6M chart
Events in this range
- May 7, 2026Earnings: -0.93; estimate -1.09; surprise 14.68%
- Aug 4, 2026Earnings: -1.36; estimate -1.28; surprise -6.25%
- Aug 31, 2026Rating: RBC Capital · Outperform → Outperform
- Aug 31, 2026Rating: Chardan Capital · Buy → Buy
- Sep 1, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 8, 2026Rating: Citigroup · — → Buy
- Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 15, 2026Rating: Chardan Capital · Buy → Buy
Signals (21)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| RSI: Oversold | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Jul 22, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 22, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
Key statistics
- Market cap
- 8.44B
- Enterprise value
- 8.33B
- Trailing P/E
- 0.00
- Forward P/E
- -12.03
- PEG ratio
- 0.00
- Price / sales
- 12.60
- Price / book
- 18.16
- EPS (TTM)
- -2.28
- Beta
- 1.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -47.79%
- Revenue (TTM)
- 669.49M
- Revenue growth
- 171.00%
- Free cash flow
- -48.63M
- Total cash
- 1.60B
- Total debt
- 1.38B
- Return on equity
- -55.21%
- Shares outstanding
- 140.86M
- Short % of float
- 10.79%
- 50-day average
- 70.34
- 200-day average
- 71.76
Analyst view
Consensus: strong buy
- Target (low)
- 74.00
- Target (mean)
- 107.71
- Target (high)
- 126.00
- Strong buy4
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 24, 2026
Expected Nov 24, 2026. Consensus EPS estimate -1.50.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 24, 2026 | Sep 30, 2026 | -1.52 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -1.28 | -1.36 | -0.08 | -6.25% |
| May 7, 2026 | Mar 31, 2026 | -1.09 | -0.93 | +0.16 | +14.68% |
| Feb 5, 2026 | Dec 31, 2025 | 0.60 | 0.22 | -0.38 | -63.33% |
| Nov 25, 2025 | Sep 30, 2025 | -0.11157 | -0.18 | -0.07 | -61.33% |
| Aug 7, 2025 | Jun 30, 2025 | -0.94 | -1.26 | -0.32 | -34.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | Chardan Capital | main | Buy | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 8, 2026 | Citigroup | init | — | Buy |
| Sep 1, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 31, 2026 | Chardan Capital | main | Buy | Buy |
| Aug 31, 2026 | RBC Capital | reit | Outperform | Outperform |
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arrowheadpharma.com
News
- Arrowhead Pharma To Present Three-Year Data From PALISADE Study And Open-Label Extension At American Heart Association Scientific Sessions 2026
- Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
- Arrowhead Pharmaceuticals’ REDEMPLO Receives UK Marketing Authorization For Familial Chylomicronaemia Syndrome; NICE Recommends NHS Funding In England And Wales For Eligible Adults With Genetically Confirmed FCS
- Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
- Top 3 Health Care Stocks That Could Blast Off In October
- Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)
- Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform
- HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target
- Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
- Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study
Your note
Sign in to keep a note on ARWR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANZALONE CHRISTOPHER RICHARD | Chief Executive Officer | Sale | Jan 1, 2026 | 3,792,740 |
| APEL DANIEL JOSEPH | Chief Financial Officer | Sale | Apr 21, 2026 | 162,905 |
| FERRARI MAURO | Director | Sale | Dec 25, 2025 | 69,053 |
| GIVEN DOUGLAS BRUCE | Director | Sale | Dec 16, 2024 | 124,167 |
| HAMILTON JAMES C | Officer | Sale | Apr 22, 2026 | 226,958 |
| LU HONGBO B | Director | Sale | May 11, 2026 | 52,012 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.53% | 14,830,553 | 888.35M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 8.06% | 11,355,555 | 680.20M | Jun 29, 2026 |
| FMR, LLC | 5.71% | 8,039,804 | 481.58M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.51% | 6,351,355 | 380.45M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.34% | 6,110,953 | 366.05M | Jun 29, 2026 |
| State Street Corporation | 4.04% | 5,694,640 | 341.11M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.57% | 5,031,501 | 301.39M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 4,246,637 | 254.37M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.18% | 3,067,819 | 183.76M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.85% | 2,603,369 | 155.94M | Aug 30, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF | 1.28% | 1,799,303 | 107.78M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.27% | 1,788,396 | 107.12M | Sep 29, 2026 |